Pfizer's Sutent, Novartis' Afinitor Earn ODAC Backing For Pancreatic Tumors

Oncologic Drugs Advisory Committee's enthusiasm for sunitinib was tempered by complexities resulting from the pivotal trial's early termination, and the panel urged that everolimus only be used for patients with aggressive disease.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet